Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to -$90.1 million.

  • Mirum Pharmaceuticals' Cash from Investing Activities rose 87.65% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.3 million, marking a year-over-year increase of 73.78%. This contributed to the annual value of -$90.1 million for FY2024, which is 15.93% up from last year.
  • As of FY2024, Mirum Pharmaceuticals' Cash from Investing Activities stood at -$90.1 million, which was up 15.93% from -$107.2 million recorded in FY2023.
  • Mirum Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $48.5 million during FY2021, with a 5-year trough of -$107.2 million in FY2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$90.1 million (2024), whereas its average is -$63.2 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Cash from Investing Activities surged by 129.64% in 2020, and later crashed by 1,492.21% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $37.9 million in 2020, then rose by 28.18% to $48.5 million in 2021, then slumped by 84.14% to $7.7 million in 2022, then slumped by 1,492.21% to -$107.2 million in 2023, then grew by 15.93% to -$90.1 million in 2024.